Collaborative initiatives and novel AI tools are helping to advance lung cancer screening, but participation barriers and disparities persist despite guideline expansions.
Key Details
- 1Lung cancer screening uptake with low-dose CT (LDCT) increased from 4.5% in 2023 to 16% in 2024, with state variation from 9.7% to 35.5%.
- 2AI deep-learning tools (e.g., from Radboud) have reduced false-positive nodule results by nearly 40%.
- 3Barriers to high screening rates include insurance preauthorization, patient knowledge, provider communication, and logistical factors.
- 4The ACR Lung Cancer Screening Registry (LCSR) is evolving into the Early Lung Cancer Detection Registry (ELCDR) to improve tracking and follow-up of both screening and incidental nodules.
- 5Guideline updates expanded eligibility, but disparities in demographic participation remain and nodule overdiagnosis is a concern.
- 6RSNA 2025 and other conferences will feature major sessions on personalized AI risk tools and screening strategies.
Why It Matters

Source
AuntMinnie
Related News

DeepHealth AI Suite Expands Radiology Insights Across Modalities
DeepHealth's Radiology AI Suite enables radiologists to detect more findings and extract additional risk and disease progression information from a wide range of imaging exams.

AI Boosts Sensitivity but Raises False Alarms in Microbleed Detection
AI significantly increases sensitivity for detecting cerebral microbleeds on brain MRI but at the cost of more false positives, highlighting the complementary strengths of AI and radiologists.

Deep Learning on PSMA-PET Outperforms Tools in Prostate Cancer Survival Prediction
Deep learning models using PSMA-PET scans predict survival in metastatic prostate cancer more accurately than established clinical tools.